Crispr Therapeutics shares tumble after significant earnings miss
Michael J. Running, the Regional President for the Americas at Plexus Corp (NASDAQ:PLXS), has recently sold a portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Running sold 1,250 shares of Plexus Corp common stock on February 21 at a weighted average price of $138.6171 per share. The transaction occurred as the stock trades near InvestingPro’s Fair Value estimate, with the company showing strong financial health and maintaining a perfect Piotroski Score of 9. The transaction, executed at prices ranging between $138.5912 and $138.92 per share, totaled $173,271.
Following this sale, Running holds 1,276 shares of Plexus Corp directly. This transaction is part of the regular reporting required for company insiders and provides insight into executive trading activities.
In other recent news, Plexus Corp’s first-quarter fiscal year 2025 earnings report revealed mixed results. While the company exceeded earnings per share (EPS) expectations by 8.7%, its revenue fell slightly short of forecasts. Despite this, analysts at Benchmark maintained a Buy rating with a $165 price target, citing strong fundamentals such as sustainable margins and free cash flow. Raymond (NSE:RYMD) James also raised its price target to $165, emphasizing Plexus’s strategic focus on domestic and near-shore manufacturing to enhance supply chain security. Needham increased its price target to $172, highlighting the company’s better-than-expected margins and confidence in a revenue increase in the latter half of the fiscal year. Stifel initiated coverage with a Hold rating and a $152 price target, noting Plexus’s strategic positioning and profitability focus. Additionally, Plexus shareholders approved all board nominees and executive compensation at the 2025 Annual Meeting. They also ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.